Peter L. Duffy, M.D.
PINEHURST – An article by FirstHealth cardiologist Peter L. Duffy, M.D., has been published in The Lancet, a leading medical journal. The article focuses on the ADAPT-DES clinical study – a prospective multicenter registry study.
Duffy, a board certified physician with FirstHealth Cardiology, was the principle investigator for the study at FirstHealth Moore Regional Hospital. The purpose of the study was to determine the relationship between platelet reactivity during dual therapy with aspirin and clopidogrel and health outcomes after a patient receives a drug-eluting stent as part of a heart catheterization procedure.
The study’s findings emphasized the counter-balancing effects of hemorrhagic and ischemic complications after stent implantation, suggesting that safer drugs or tailored strategies for the use of more potent agents must be developed if the benefits of greater platelet inhibition in patients with cardiovascular disease are to be realized.
Of the 8,651 patients enrolled throughout the United States for this trial, 549 were enrolled in the FirstHealth Clinical Trials program at Moore Regional.
The research opportunities at FirstHealth are part of the same clinical trial research programs found at the country’s leading academic hospitals and major medical centers. They include studies related to heart and vascular, ENT, gynecology and oncology.
For more information on clinical trials at FirstHealth, visit www.firsthealth.org/clinicaltrials or call (910) 715-2200.